Press Room

DPI China 2024

Start
Thursday, March 21, 2024
End
Thursday, March 21, 2024
Location: Hangzhou, China
DPI China_2024_Hovione

Looking for a complete One-Site Solution for your inhalation and nasal therapies? Meet Hovione at the 11st DPI China Technology Conference! Delivering solutions every breath of the way.

We live and breathe innovation for the successful delivery of your inhalation and nasal therapies.

Hovione offers customized high-performance APIs, particle engineering and formulation along with a full range of highly specialized, patented and innovative devices, all in one site.

Don’t miss the chance to speak with our Inhalation Experts. 

On March 21, our team is at the 11th DPI China Technology Conference ready to share how this integration on a single site can support your project.

ORAL PRESENTATION – March 21

"End-to-end Respiratory Drug Delivery Platforms", with João Ventura, Product Management Director, Business Management Products.

The presentation will provide a perspective on the status and outlook of respiratory drug delivery and address the most relevant platforms for end-to-end dry powder inhalation (DPI) development, as DPIs are the dosage form of choice for achieving superior delivery efficiency to patients.

This presentation will focus on advanced particle engineering technologies for manufacturing inhalation active pharmaceutical ingredients (APIs), new formulation development platforms, aiming to address the pharmacokinetics requirements of the target drug and indication, and device developments for maximum drug delivery efficiency for lung delivery. An integrated, end-to-end development approach will be presented designed to maximize drug delivery efficiency and safety and address a diversified array of diseases.

 

Schedule a meeting today.

Learn more about our Inhalation and Nasal offering.

 

 

Also in the Press Room

See All

The global inhalation contract development and manufacturing organization (CDMO) market is projected to grow from USD 9.13 billion in 2025 to USD 16.68 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.7% during the forecast period. This growth is driven by the increasing prevalence of respiratory diseases, advancements in inhalation drug delivery technologies, and the rising demand for outsourced manufacturing services in the pharmaceutical industry. The inhalation CDMO market has emerged as a pivotal segment in the pharmaceutical contract development and manufacturing industry. With a rising demand for inhaled therapies for conditions like asthma, COPD, and cystic fibrosis, companies are increasingly outsourcing drug development and production to specialized partners. Inhalation CDMO services cater to both large pharmaceutical corporations and small biotech firms, offering expertise in formulation, device compatibility, regulatory support, and scale-up manufacturing. This market is gaining traction due to the complexity of inhalation drug delivery, which often requires niche technical capabilities and specialized equipment. Outsourcing to an inhalation CDMO allows drug developers to reduce time-to-market while ensuring quality and compliance with global standards. (...) Top Companies Several players dominate the inhalation CDMO market through technological expertise, global reach, and service portfolio diversity: (...) Hovione – Offers particle engineering and inhalation development, with a focus on dry powder inhalers. (...) These companies are continually investing in facilities, talent, and technology to meet evolving customer needs in the inhalation CDMO market.   Read the full article on Pharmiweb.com        

Press Clipping

Inhalation CDMO Market Growth Analysis & Forecast 2025 to 2035

Jun 25, 2025